ANGIODYNAMICS INC ANGO
ANGIODYNAMICS INC (ANGO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $320.2M at a -11.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.09 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.329 |
| Retained earnings / assets | -1.532 |
| EBIT / assets | -0.143 |
| Equity / liabilities | 1.883 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ANGO | ANGIODYNAMICS INC | 5/9 | -1.82 | — | +9.5% |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | 7/9 | 8.52 | 35.8 | +12.5% |
| PRCT | PROCEPT BioRobotics Corp | 3/9 | 2.18 | — | +37.2% |
| SKIN | SkinHealth Systems Inc. | 6/9 | -1.89 | — | -10% |
| LMAT | LEMAITRE VASCULAR INC | 6/9 | 8.18 | 37.9 | +13.5% |
| KIDS | ORTHOPEDIATRICS CORP | 4/9 | 2.67 | — | +15.4% |
| CERS | CERUS CORP | 4/9 | -13.54 | — | +16.1% |
About ANGIODYNAMICS INC
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
FAQ
Is ANGO financially healthy?
ANGIODYNAMICS INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ANGO pay a dividend?
No, ANGIODYNAMICS INC does not currently pay a dividend.
How profitable is ANGO?
In FY2025, ANGIODYNAMICS INC had a net margin of -11.5% and a return on equity of -21.5%.
Is ANGO overvalued or undervalued?
ANGIODYNAMICS INC trades at about 9.6× trailing earnings — below its 10-year norm (10-year range 12.0×–233.3×, median 115.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ANGO?
The average Wall-Street price target for ANGIODYNAMICS INC is $18.00, about 14.3% above the recent price, from 4 analysts.
Is ANGO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ANGIODYNAMICS INC: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-05-31. Facts plus Stocktoria's own computed scores — not investment advice.